ArticleNature2023
Genomic-transcriptomic evolution in lung cancer and metastasis.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers.
0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed
46.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 188 citations in OpenAlex.
- Trial
- Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non‑small cell lung cancer (Review).Oncology reports · 2026Review
- ClonalLife science alliance · 2026Article
- Multifocal ground-glass opacities in lung cancer: a narrative review of genomic evolution, immune ecology, and biology-informed clinical management.Journal of thoracic disease · 2026Review
- Distinct Spatial Immune Architectures in Tumor and Tumor-Adjacent Tissues of Early-Stage Non-Small Cell Lung Cancer.bioRxiv : the preprint server for biology · 2026Article
- Multiregion profiling of genomic and transcriptional heterogeneity in head and neck squamous-cell carcinoma.ESMO open · 2026Article
- Hallmarks of lung cancer driven by inhalable particulate matter: From cell-intrinsic oncogenic traits to microenvironment remodeling.Innovation (Cambridge (Mass.)) · 2026Review
- Charting intratumor heterogeneity from bench to bedside.Nature cancer · 2026Review
- Unraveling CD4Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Interpretable deep learning model of circulating genomics for quantitative survival prediction in advanced non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Clinical overall survival prediction and disease characteristics of locally advanced non-small cell lung cancer: an integrated analysis based on the SEER and TCGA databases.Translational cancer research · 2026Article
- Article
- Editing regulatory network in non-small cell lung cancer: implications for immunity and metastasis.Human genomics · 2026Article
- APOBEC3A is the predominant global editor of cytosines in human mRNAs and in single-strand RNA viruses.G3 (Bethesda, Md.) · 2026Article
- Biomolecular profiling for noninvasive health monitoring.Nature biotechnology · 2026Review
- Unannotated noncoding transcripts as a source of intratumor heterogeneity in malignant cell states.Science China. Life sciences · 2026Article
- Diagnostic importance of serum markers in lung cancer.Molecular medicine reports · 2026Article
- Decoding immunotherapy response through computational modeling.Nature communications · 2026Review
- An Interpretable Machine Learning Model With Synthetic MRI-Based Habitat Radiomics for Predicting Lymph Node Metastasis in Oral Cancer.Cancer medicine · 2026Article
- Aging Associated Transcriptomic Signatures in Tumor and Tumor Adjacent Lung Tissues Associated with Recurrence Following Resection of Stage I Lung Adenocarcinoma.Research square · 2026Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
47 authors at 20 institutions in 9 countries.
Carlos Martínez-Ruiz *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-4817-0565
James R M Black *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Clare Puttick *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Mark S Hill *Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0003-0718-8934
Jonas DemeulemeesterCancer Genomics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-2660-2478
Elizabeth Larose CadieuxCancer Genomics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-9320-8040
Kerstin TholCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-4624-118X
Thomas P JonesCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Selvaraju VeeriahCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cristina Naceur-LombardelliCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Antonia TonchevaCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Paulina PrymasCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Andrew RowanCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.
Sophia WardCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-6777-5279
Laura CubittAdvanced Sequencing Facility, The Francis Crick Institute, London, UK.
Foteini AthanasopoulouCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Oriol PichCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-1956-1882
Takahiro KarasakiCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-6863-2360
David A MooreCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-6296-1312
Roberto SalgadoDepartment of Pathology, ZAS Hospitals, Antwerp, Belgium.ORCID http://orcid.org/0000-0002-1110-3801
Emma ColliverCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-1497-0740
Carla CastignaniCancer Genomics Laboratory, The Francis Crick Institute, London, UK.
Michelle DietzenCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-6853-7563
Ariana HuebnerCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-8009-4999
Maise Al BakirCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-0846-8332
Miljana TanićMedical Genomics, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0003-3102-776X
Thomas B K WatkinsCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.
Emilia L LimCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Ali M Al-RashedCentre for Nephrology, Division of Medicine, University College London, London, UK.ORCID http://orcid.org/0000-0003-4280-1677
Danny LangScientific Computing STP, Francis Crick Institute, London, UK.
James ClementsScientific Computing STP, Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-7837-7807
Daniel E CookCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0003-3347-562X
Rachel RosenthalCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.
Gareth A WilsonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute and University College London Cancer Institute, London, UK.
Alexander M FrankellCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-0341-7878
Sophie de Carné TrécessonOncogene Biology Laboratory, The Francis Crick Institute, London, UK.
Philip EastBioinformatics and Biostatistics, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-5801-5713
Nnennaya KanuCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Kevin LitchfieldCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Nicolai J BirkbakCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0003-1613-9587
Allan HackshawCancer Research UK & UCL Cancer Trials Centre, London, UK.ORCID http://orcid.org/0000-0002-5570-5070
Stephan BeckMedical Genomics, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-5290-2151
Peter Van LooCancer Genomics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-0292-1949
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0003-1212-1259
TRACERx Consortium
Charles SwantonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. Charles.Swanton@crick.ac.uk.ORCID http://orcid.org/0000-0002-4299-3018
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.ORCID http://orcid.org/0000-0001-9537-4045
The Francis Crick Institute · GBCancer Research UK · GBLondon Cancer · GBRoyal London Hospital · GBGuy's and St Thomas' NHS Foundation Trust · GBManchester University NHS Foundation Trust · GBUniversity Hospitals of Leicester NHS Trust · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity of Leicester · GBUniversity Hospital Southampton NHS Foundation Trust · GBUniversity College Hospital · GBUniversity College London · GBGolden Jubilee National Hospital · GBAarhus University · DKAberdeen Royal Infirmary · GBInstitute of Cancer Research · GBUniversity of Manchester · GBCancer Research UK Manchester CentreThe Christie NHS Foundation Trust · GBThe University of Texas MD Anderson Cancer Center · US
Funding
Cancer Research UK 17786Cancer Research UK 21999Cancer Research UK 24956Cancer Research UK 29569Cancer Research UK 30025Cancer Research UK CTRNBC-2022/100001Medical Research Council MR/L016311/1Medical Research Council MR/P014712/1Medical Research Council MR/V033077/1Medical Research Council MR/W025051/1Wellcome Trust CC2008Wellcome Trust CC2041
Abstract
Intratumour heterogeneity (ITH) fuels lung cancer evolution, which leads to immune evasion and resistance to therapy
Indexed as
Evolution, MolecularGenome, HumanLung NeoplasmsNeoplasm MetastasisTranscriptomeAdenosine DeaminaseAllelesCarcinoma, Non-Small-Cell LungCytidine DeaminaseGenomicsHumansMachine LearningMutationProteinsRNA-Binding ProteinsADAR protein, humanAdenosine DeaminaseAPOBEC3A protein, humanCytidine DeaminaseProteinsRNA-Binding Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.